AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease 2019 (COVID-19)
Conditions
Coronavirus Disease 2019 (COVID-19)
Trial Timeline
Jun 9, 2022 → Oct 4, 2023
NCT ID
NCT05375760About AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) is a phase 2 stage product being developed by AstraZeneca for Coronavirus Disease 2019 (COVID-19). The current trial status is terminated. This product is registered under clinical trial identifier NCT05375760. Target conditions include Coronavirus Disease 2019 (COVID-19).
What happened to similar drugs?
0 of 12 similar drugs in Coronavirus Disease 2019 (COVID-19) were approved
Approved (0) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05375760 | Phase 2 | Terminated |
Competing Products
20 competing products in Coronavirus Disease 2019 (COVID-19)